**ADRENALINE**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Manner of administration and formI.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector  | Max.Qty | №.of Rpts | Dispensed Price for Max. Qty | Proprietary Name and Manufacturer |
| DRUG NAME (IN CAPITALS)**ADRENALINE**{Forms(s)} {strength(s)}Auto-Injector 150 microgram/0.3 mL injection: solution, 1 x 0.3 mL syringe | 1 | 0 | $106.34 | **ANAPEN** Link Medical Products Pty Ltd |  |
|  |
| **Category /** **Program** | General Schedule (Code GE) |
| **Prescriber type:** | [ ] Dental [x] Medical Practitioners [ ] Nurse practitioners [ ] Optometrists[ ] Midwives |
| **Episodicity:** | Acute |
| **Severity:** | N/A |
| **Condition:** | allergic reaction with anaphylaxis |
| **PBS Indication:** | Acute allergic reaction with anaphylaxis |
| **Treatment phase:** | Initial sole PBS-subsidised supply for anticipated emergency treatment |
| **Restriction Level / Method:** | [ ] Restricted benefit[x] Authority Required - In Writing[x] Authority Required - Telephone[x] Authority Required – Emergency[x] Authority Required - Electronic[ ] Streamlined |
| **Treatment criteria:** | N/A |
| **Clinical criteria:** | * Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a clinical immunologist; **OR**
* Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with an allergist; **OR**
* Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a paediatrician; **OR**
* Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a respiratory physician.
 |
| **Population criteria:** | N/A |
| **Foreword** | N/A |
| **Definitions** | N/A |
| **Prescriber Instructions** | The name of the specialist consulted must be provided at the time of application for initial supply. |
| **Administrative Advice** | * The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au.)
* Authority approvals will be limited to a maximum quantity of 2 auto-injectors (Anapen or EpiPen) at any one time.
* No applications for repeats will be authorised.
 |
| **Cautions** | EpiPen and Anapen products have different administration techniques and should not be prescribed to the same patient without training in their use. |